Neurology Research Review Focusing Specifically on MS

In this issue, an analysis of MSBase data shows that initial treatment with fingolimod, alemtuzumab, or natalizumab is associated with a lower risk of conversion to secondary progressive MS than initial treatment with glatiramer acetate or beta-interferon in patients with RRMS. A preliminary study of patients with RRMS shows that HSCT prolongs the time to disease progression compared with DMT, and another MSBase analysis reports that DMTs have no substantial effect on disability outcomes in patients with PPMS. A Canadian study reports that approximately 10% of individuals discontinue their first oral DMT within 6 months and 20% do so within one year, and a UK study suggests that a personalised protocol of subcutaneous cladribine may be a viable therapeutic option in MS patients who are ineligible for treatment with oral DMTs.

Neurology Research Review Supplement: Multiple Sclerosis Issue 55 2019

Courtesy of Research Review.